Best adjuvant (assist) for chemotherapy | 1+1>487% |
Effectively improve chemotherapy effect, treatment, immunity.
Reduce side effects and recurrence.
Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work |
Abstract / Summary / Overview of Apoptosis.
Why do cells undergo apoptosis?
The relationship between cancer cells and apoptosis.
Where are the weaknesses and symptoms of cancer cells?
Are cancer cells aggressive?
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)
Solamargine's major function mechanism:
Solamargine vs cancer
Best Chemotherapy Adjuvant. (1+1>478%)
Effectively improve chemotherapy effect and cure.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Extract : https://www.uchicagomedicine.org/cancer/types-treatments/ovarian-cancer/mucinous-ovarian-cancers
Mucinous Ovarian Cancers
Mucinous ovarian cancer is a rare subtype of ovarian cancer. About 2-3% of new ovarian cancers are mucinous (cells are large and filled with fluid), meaning that most of the tumor is made up of cells coated in mucus.
Symptoms and Diagnosis
Many patients with this type of ovarian cancer will have a very large ovarian mass and might experience symptoms such as:
- Bloating
- Pain
- Feeling full quickly
- Feeling a mass in your belly
- Fatigue
Because of these symptoms, and the fact that these tumors are rather large, mucinous ovarian cancer is sometimes found earlier than other types of ovarian cancer. Unfortunately, it has often spread by the time it is diagnosed. One of the unique characteristics of mucinous ovarian cancer is that, under the microscope, it can appear similar to cancers that arise from the gastrointestinal (GI) tract. Due to these similarities, it can be difficult to distinguish whether it is truly ovarian cancer or cancer that has spread from a different part of the body. For this reason, it is imperative that the correct diagnosis is made.
Whether you come to the University of Chicago Medicine for surgery or if it was done elsewhere and you come to us for another opinion, our gynecologic pathologists have extensive experience evaluating rare ovarian cancers and are highly skilled at making the correct diagnosis.
Initial Treatment
Like other types of ovarian cancer, surgery is often an important component of treatment. We have a team of gynecologic cancer surgeons who are experienced in treating mucinous ovarian cancer. For patients of childbearing age, we consult with reproductive endocrinologists to develop a fertility-sparing treatment plan to give the patient a chance to carry a pregnancy in the future. For more advanced mucinous ovarian cancers, treatments can include aggressive surgical procedures to remove areas where cancer has already spread.
In select patients, we may consider adding heated intraperitoneal chemotherapy (HIPEC) at the time of surgery, which is performed in partnership with our surgical oncology team. In cases where cancer has spread, and in some cases where it is diagnosed earlier in its course, chemotherapy may be recommended. This decision is usually based on findings at the time of surgery and the gynecologic pathologist’s final diagnosis after careful review of the case.
Even if you do not live in the Chicago area, we have experience giving expert second opinions after we obtain relevant imaging and pathology and laboratory results from your physician. In some instances, second opinion cases are presented at multidisciplinary tumor board meetings.
Abstract / Summary / Overview of Apoptosis.
Overview of apoptosis
•Programmed cell death.
•Apoptosis is a form of programmed cell death, or “cellular suicide.”
•Apoptosis is different from necrosis, in which cells die due to injury.
•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.
Why do cells undergo apoptosis?
- Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
- Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
- Apoptosis is part of development
- In many organisms, programmed cell death is a normal part of development.
The relationship between cancer cells and apoptosis.
Apoptosis can eliminate infected or cancerous cells.
When a cell’s DNA is damaged, it will typically detect the damage and try to repair it.
If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA.
When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.
However, “successful” cancer cells successfully evade the process of apoptosis.
This allows them to divide out of control and accumulate mutations (changes in their DNA).
Apoptosis is key to immune function.
Apoptosis also plays an essential role in the development and maintenance of a healthy immune system.
Where are the weaknesses and symptoms of cancer cells?
The symptoms of cancer cells are in the nucleus.
The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.
DNA mutations also mutate in the nucleus.
Therefore, to treat cancer cells, we must first enter the nucleus.
Let the “regulatory cell gene” mechanism enter the nucleus to regulate.
Are cancer cells aggressive?
After the action of Solamargine, the aggressiveness of cancer cells is alleviated.
So after using Solamargine, many patients feel that I am half better.
Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work).
Solamargine's major function mechanism:
When Solamargine enter,
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant. (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
